Finerenone

Use of finerenone was associated with a statistically significant 25% relative reduction in urine albumin-to-creatinine ratio compared with placebo over 6 months in patients with type 1 diabetes and chronic …

Finerenone (Kerendia) significantly reduced urine albumin-to-creatinine ratio (UACR) by 25% from baseline to 6 months compared with the placebo for patients with type 1 diabetes (T1D) and chronic kidney disease …

NEW YORK, Nov. 6, 2025 /PRNewswire/ — Results of the Bayer-led Phase 3 FINE-ONE clinical trial, presented at the American Society of Nephrology Kidney Week in Houston, demonstrate that finerenone significantly …

The drug finerenone has a positive effect on patients with type 1 diabetes and chronic kidney disease. The drug reduces the amount of proteins excreted in the urine of these …

The study adhered to the ethical principles of the Declaration of Helsinki33 and followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline. Ethical approval for this study …